UiPath, Inc. (PATH) Stock Price & Analysis

UiPath, Inc. (PATH) closed at USD 13.94 on Thursday, October 22, 2026, up 1.68% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 13.71; the Oct 22, 2026 session ranged USD 13.55–14.1 on volume of 36,263,938 shares. Market capitalization is $7.26B, with a 52-week range of USD 9.2–19.84 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:48 UTC.

Also available as compact Markdown for AI agents: nexqual.com/PATH.md

Key facts (PATH)

• Last four reported quarters (through Jul 31, 2026): revenue $1.72B, net income $362M (21.0% margin), free cash flow $363M (SEC filings).
• Valuation: P/E 20.1x (avg 24.3x at the last 1 fiscal year-ends).
• Insider open-market sales, last ~7 months: 9 Form 4 filings, $61.6M; 0 not under a Rule 10b5-1 plan ($0K); 1 by opportunistic insiders (0 outside 10b5-1 plans), 2 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Hold (mean 3.00 on a 1–5 scale) (21 analysts), mean target USD 15.32 (range 10–23).
• Total return with dividends: 1Y -9.7% vs S&P 500 +14.9%; 5Y -72.6% vs S&P 500 +80.3%.
• Next earnings: 2026-12-02, EPS estimate USD 0.19, revenue estimate $443M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PATH)

Fiscal years end Jan. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jul 31, 2026) (PATH)

P/E 20.1x · P/S 4.2x · P/FCF 20.0x · P/B 3.7x · FCF yield 5.00% · Earnings yield 4.98% · Buyback yield (TTM) 3.70%

P/E at fiscal year-ends: Jan 2026 24.3x.

Insider sales (SEC Form 4, open-market, last ~7 months) (PATH)

9 of 9 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (PATH)

Consensus Hold (mean 3.00 on a 1–5 scale), 21 analysts; mean target USD 15.32 (low 10, high 23).

Rating changes, last 120 days:

Total return (dividends reinvested) (PATH)

PATH revenue by product line (quarter ended Jul 31, 2026)

PATH revenue by region (quarter ended Jul 31, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

PATH company outlook (results filed Sep 3, 2026)

• “Eastern Time, to discuss the Company's second quarter fiscal 2027 financial results and its guidance for the third”

Quoted word-for-word from the SEC 8-K results press release.

PATH analyst estimates and revisions

PATH options: expected move

Options price a move of about ±16.8% (±$2.32) by Dec 4, 2026, which includes earnings on Dec 2, 2026; the earnings reaction alone is priced at about ±7.3%. Over the last 8 reports the stock moved ±9.8% on average.

30-day implied volatility 52.2% vs 44.9% realized over the last 30 trading days. Put/call ratio (volume) 0.17. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 09:48 UTC)

Technical Analysis (PATH)

Nexqual's technical model rates PATH "NEUTRAL" based on 3 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 09:48 UTC.

Analyst Ratings (PATH)

Wall Street analysts rate PATH "Hold" based on 21 analysts, with a mean price target of USD 15.32 (range USD 10–23), per Nexqual as of October 23, 2026 at 09:48 UTC.

Earnings (PATH)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 09:48 UTC.

Financials & Fundamentals (PATH)

Source: Nexqual, October 23, 2026 at 09:48 UTC.

Financial Health Score (PATH)

Nexqual rates UiPath, Inc.'s overall financial health "Strong" across five dimensions, as of October 23, 2026 at 09:48 UTC.

Ownership (PATH)

Source: Nexqual, October 23, 2026 at 09:48 UTC.

Leadership (PATH)

UiPath, Inc. is led by Daniel Solomon Dines, Co-Founder, CEO, & Executive Chairman of the Board, per Nexqual as of October 23, 2026 at 09:48 UTC.

Major Backers & Investors (PATH)

Notable institutional backers of UiPath, Inc. include Tetragon Partners GP Ltd., Two Sigma Investments, LP, Senvest Management LLC, according to Nexqual as of October 23, 2026 at 09:48 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 09:48 UTC.

From UiPath, Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)

Key Strengths & Strategy (as disclosed to the SEC)

• Our platform empowers customers to combine automation, AI agents, and people, delivering end-to-end process orchestration that drives innovation.
• We host and present regularly at regional and global events, including our own Fusion and On Tour conferences, and Summit and DevCon events.
• We rely on a combination of patent, copyright, trademark, and trade secret laws in the U.S. and other jurisdictions, as well as license agreements, confidentiality procedures, non-disclosure agreements with third parties, and other contractual protections, to protect our intellectual property rights, including our proprietary technology, software, know-how, and brand.
• Although we rely on intellectual property rights, including patents, copyrights, trademarks, and trade secrets, as well as contractual protections to establish and protect our proprietary rights, we believe that factors such as the technological and creative skills of our personnel, development of new services, features, and functionality, and frequent enhancements to our platform are equally essential to establishing and maintaining our technology leadership position.

Legal & Regulatory Risks (Item 1A, quoted)

• We are subject to anti-corruption, anti-bribery, anti-money laundering, and similar laws, and noncompliance with such laws can subject us to criminal or civil liability and harm our business, financial condition, and results of operations.
• Government contracting requirements may also change and in doing so restrict our ability to sell into the government sector until we have attained the requisite approvals. Government demand and payment for our products are affected by public sector budgetary cycles and funding authorizations, with funding reductions or delays adversely affecting public sector demand for our products.
• We are subject to governmental export and import controls that could impair our ability to compete in international markets or subject us to liability if we violate the controls.
• Our business activities are subject to Trade Controls which may prohibit or restrict the sale or supply of certain products, including encryption items and other technology, and services to certain governments, persons, entities, countries, and territories, including those that are the target of comprehensive sanctions.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:48 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt